MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
37.72
-1.40
-3.58%
After Hours: 37.90 +0.18 +0.48% 19:07 08/28 EDT
OPEN
38.73
PREV CLOSE
39.12
HIGH
39.62
LOW
37.40
VOLUME
469.18K
TURNOVER
--
52 WEEK HIGH
47.84
52 WEEK LOW
8.29
MARKET CAP
2.37B
P/E (TTM)
-8.9959
1D
5D
1M
3M
1Y
5Y
1D
Notable Wednesday Option Activity: ZVRA, KOD, PEN
NASDAQ · 2d ago
Weekly Report: what happened at KOD last week (0817-0821)?
Weekly Report · 4d ago
Kodiak Sciences Advances ALTO Phase 3 Trial In Diabetic Eye Disease
TipRanks · 08/21 16:32
3 Best Stocks With 75%+ Upside to Buy This Week, According to Analysts
TipRanks · 08/17 21:20
Kodiak Sciences Price Target Maintained With a $58.00/Share by HC Wainwright & Co.
Dow Jones · 08/17 11:57
HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $58 Price Target
Benzinga · 08/17 11:46
Analysts Are Bullish on These Healthcare Stocks: Kodiak Sciences (KOD), ProQR (PRQR)
TipRanks · 08/17 11:30
Weekly Report: what happened at KOD last week (0810-0814)?
Weekly Report · 08/17 10:05
More
About KOD
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.